drugset
drugset / Trial / NCT05519865

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

NCT05519865 ↗

Phase 2 Completed 118 enrolled Chipscreen Biosciences, Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-blind, Controlled, Multi-center Phase 2 Clinical study to Investigate the Efficacy and Safety of Tucidinostat (Chidamide) Combined with Tislelizumab as First-line Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Timeline

Start
2022-10-26
Primary completion
2024-11-18
Completion
2024-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Subject Tucidinostat Small molecule 30 mg Oral

Indications

non-small cell lung carcinoma